



Short version of press release from Emotra AB
Gothenburg October 1, 2013

Emotra files patent application

- *Emotra's EDOR is used to test hyporeactivity, which is closely related to suicide risks*
- *EDOR is mainly protected by software in the form of mathematical algorithms*
- *A patent application describing a possible hardware improvement is now filed*

Emotra's most important product protection is the mathematical algorithms for the analyses of the curves, resulting from measurement with EDOR. Many years of clinical research and documentation work has been the basis for the development of the above mentioned algorithms. The Company has earlier concluded that the protection of the product system will be even stronger without a software patent. Without knowledge about Emotra's algorithms, a possible future competitor would have to perform their own clinical studies in order to develop similar tools, absolutely necessary components for the analysis of electrodermal measurements.

In order to protect the possibilities to improve the already high accuracy even further (97 %), Emotra has filed a patent application describing a possible improvement of the hardware as well as of the measurement technology. The patent application has been filed to the Swedish patent office. The company will wait for the response from the Swedish authority before deciding on filing a PCT-application.

Emotra is at present in a very dynamic phase and its activities involve an increasing number of clinical centers. In order to minimize the financial risks, all work is done in a small organization and in such a cost effective manner as possible. When the support for EDOR from these clinical teams, is strong enough, the method will be launched in Europe.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se

or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, lars@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se